the experimental drug retatrutide (Eli Lilly and Company) produces the greatest weight loss. The review, conducted by researchers at McGill University, Montreal, Quebec, Canada, examined three ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

An experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight. Randomized controlled trials (RCTs) assessed the efficacy and safety of ...

Semaglutide produced nearly 14% weight loss after 68 weeks. Retatrutide generated weight loss of more than 22% after 48 weeks. Each of those drugs are taken once a week, by an injection.

Those who received GLP-1s experienced decreased absolute and relative weight loss vs. placebo across 26 randomized studies. Retatrutide conferred the greatest weight reduction among all GLP-1s.

Retatrutide (12 mg once weekly) resulted in weight loss of up to 22.1% after 48 weeks; other novel single and combination GLP-1 agents were also efficacious. Adverse events were frequent (80 to 97 ...

Retatrutide, tirzepatide, and semaglutide were most effective for weight loss in adults without diabetes, showing significant reductions in body weight and BMI. Retatrutide led the investigative ...